# Third Line Antiretroviral Treatment Optimization in Sub-Saharan Africa

> **NCT02025868** · PHASE2 · UNKNOWN · sponsor: **ANRS, Emerging Infectious Diseases** · enrollment: 201 (actual)

## Conditions studied

- HIV Infection

## Interventions

- **BEHAVIORAL:** adherence reinforcement
- **DRUG:** Antiretroviral Therapy Darunavir/r + Raltegravir + 2 NRTIs (as chosen by the investigators)

## Key facts

- **NCT ID:** NCT02025868
- **Lead sponsor:** ANRS, Emerging Infectious Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-03
- **Primary completion:** 2016-08
- **Final completion:** 2017-05
- **Target enrollment:** 201 (ACTUAL)
- **Last updated:** 2017-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02025868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02025868, "Third Line Antiretroviral Treatment Optimization in Sub-Saharan Africa". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02025868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*